Press releases

One-year results from the SPIRIT III trial included an updated analysis of 1,002 patients with coronary artery disease

Data showed continued low incidences of adverse events and repeat revascularization through two years in complex patients

"The quarter represented a turn for us, with a number of positive developments," said Jim Tobin, President and Chief Executive Officer

Approximately 2,300 positions to be eliminated worldwide

Schedule of Company events for the Cardiovascular Research Foundation's (CRF) 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium

CE Mark for CONFIENT™ implantable cardioverter defibrillator (ICD) represents first Boston Scientific-branded cardiac rhythm management device to treat sudden cardiac death

A live webcast and replay of the October 19 conference call will be available

Data reflects the experience from the first 15,000 patients monitored wirelessly on the LATITUDE® Patient Management System

With the election of Mr. Elliott, the Boston Scientific Board increases to 15 members

Analysis of TAXUS II, IV, V and VI trials found paclitaxel-eluting stents had similar clinical outcomes in women and men, despite women’s higher risk profile

TAXUS® Stent shows no additional very late stent thrombosis

OLYMPIA launch phase results show positive outcomes in diabetic patients

Three Boston Scientific subsidiaries will pay a total of $16.75 million and admit no liability

Company plans to announce five-year results from the TAXUS II clinical trial

A live webcast and replay of the September 10 conference session will be available

Amendment to provide the Company additional financial flexibility as it implements initiatives designed to increase shareholder value

Transaction would advance company's plan to divest non-strategic assets and strengthen operating and financial performance

BSC to assume sole control of Pain Management business and emerging indications program, Advanced Bionics principals to purchase Auditory business and drug pump program

Endosurgery group to remain wholly owned by Boston Scientific

Business produces a range of products used to manage fluid and measure pressure during angiography and angioplasty procedures

"We made progress in a number of key areas during the quarter," said Jim Tobin, President and Chief Executive Officer

TAXUS PERSEUS clinical program to evaluate platinum enhanced drug-eluting stent

Successful implantation marks the beginning of the TAXUS PETAL I First Human Use (FHU) Trial

Claims associated with a series of product communications issued by Guidant Corporation in 2005 and 2006; Company acquired Guidant Corporation last year

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2007...